^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1 expression + CTLA4 expression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, CTLA4, Cytotoxic T-Lymphocyte Associated Protein 4, Insulin-Dependent Diabetes Mellitus 12, Cytotoxic T-Lymphocyte Protein 4, Celiac Disease 3, CTLA-4, CD152, Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cyto
Entrez ID:
Related biomarkers:
7ms
Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis. (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi)
Therefore, interference with specific immune cells in innate immunity can regulate the expression of CTLA4 and/or PD-L1 to a certain extent, inhibit tumor immune escape, and delay the progression of oral mucosal carcinogenesis.
Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
11ms
Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade? (PubMed, Appl Immunohistochem Mol Morphol)
This analysis highlights the homogenous molecular and immune profile of eGB and PXA, suggesting the possibility that histologically and molecularly, these two entities represent 2 ends of a continuous spectrum with PXAG3 lying in between. Higher upregulation of PDL1, CTLA-4, and increased tumor infiltrating lymphocytes in these tumors as compared with GB, IDH wt suggests potential candidature for immunotherapy.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ATRX (ATRX Chromatin Remodeler) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • TP53 mutation • BRAF V600E • BRAF V600 • IDH1 mutation • EGFR amplification • CDKN2A deletion • IDH wild-type • CTLA4 expression • IDH1 wild-type + BRAF mutation • PD-L1 expression + CTLA4 expression
1year
Comprehensive analysis of HOXC8 associated with tumor microenvironment characteristics in colorectal cancer. (PubMed, Heliyon)
HOXC8 overexpression was associated with poor prognosis and specific TME subtypes in CRC. This study provided valuable resource for further exploring the potential mechanisms and therapeutic targets of HOX genes in CRC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HOXC8 (Homeobox C8)
|
PD-L1 expression • TMB-H • CTLA4 expression • HOXC8 overexpression • PD-L1 expression + CTLA4 expression
1year
Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma. (PubMed, Int J Immunopathol Pharmacol)
Furthermore, IL2 expression was positively correlated with PD-1, PD-L1, and CTLA-4 expression. Our results indicate that down-regulation of IL2 predicts poor prognosis and is associated with immune escape in LUAD, and IL2 could serve as a potential novel prognostic biomarker of LUAD.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
PD-L1 expression • CTLA4 expression • IL2 expression • IL2-L • PD-L1 expression + CTLA4 expression
1year
Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG). (PubMed, World J Urol)
Intravesical BCG combination treatment seems to effectively prevent BC development in an immunecompetent clinically relevant animal model, introducing Thalidomide, Nitazoxanide, and specially Rapamycin as candidates in the intravesical immunotherapy advancement. Our study contributes in understanding the mechanism of cancer immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker • Immunomodulating
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
|
sirolimus • thalidomide
over1year
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. (PubMed, NPJ Precis Oncol)
Anti-CD47 showed potent anti-tumor activity and synergized with PARPi in OC models. These data support clinical development of anti-CD47 therapy with PARPi in OC.
Preclinical • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD47 (CD47 Molecule) • BRCA (Breast cancer early onset) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TGFB1 (Transforming Growth Factor Beta 1) • BRD4 (Bromodomain Containing 4) • SIRPA (Signal Regulatory Protein Alpha)
|
PD-L1 expression • CD47 overexpression • CD47 expression • CTLA4 expression • CXCL12 expression • CXCR4 expression • PD-L1 expression + CTLA4 expression
over1year
High DNA methylation age deceleration defines an aggressive phenotype with immunoexclusion environments in endometrial carcinoma. (PubMed, Front Immunol)
Thus, the tumor suppressive function of aging-like DNA hypomethylation is severely impaired in hDNAmad+ tumors, likely due to enhanced expression of DNMT3A/3B and dysregulated aging regulators. Our findings not only enrich biological knowledge of EC pathogenesis but also help improve EC risk stratification and precision ICI immunotherapy.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Epigenetic controller
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • RB1 (RB Transcriptional Corepressor 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
PD-L1 expression • TMB-L • VTCN1 underexpression • CTLA4 expression • PD-L1 expression + CTLA4 expression
over1year
Nifuroxazide inhibits the growth of glioblastoma and promotes the infiltration of CD8 T cells to enhance antitumour immunity. (PubMed, Int Immunopharmacol)
we found that nifuroxazide can inhibit the growth of glioblastoma and enhance antitumour immunity. Thus, nifuroxazide is an effective drug for the treatment of glioblastoma and has great potential for clinical application.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
|
CTLA4 expression • PD-L1 expression + CTLA4 expression
over1year
Prevalence and spatial interplay of mononuclear phagocyte and lymphocyte subpopulations in 49 carcinoma entities in respect to its TIM3, PD-1, PD-L1 and CTLA-4 expression using BLEACH&STAIN (AACR 2023)
These data support the concept that among most carcinoma entities at least some individual patients may benefit from treatment with immune checkpoint inhibitors.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • ITGAX (Integrin Subunit Alpha X)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
almost2years
Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma. (PubMed, Clin Transl Oncol)
ARGs play an important role in TME diversity and complexity in HCC patients. The ARG score of HCC predicts TME invasion and can guide immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
CTLA4 expression • PD-L1 expression + CTLA4 expression
almost2years
Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. (PubMed, ESMO Open)
This study highlights the immunological differences between primary BCs and BCBMs and the potential importance of ARG2 expression in T-cell depletion and clinical outcome.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • ARG2 (Arginase 2)
|
PD-L1 expression • ER positive • EGFR positive • CTLA4 expression • PD-L1 expression + CTLA4 expression
2years
Comprehensive analysis of PTPN gene family revealing PTPN7 as a novel biomarker for immuno-hot tumors in breast cancer. (PubMed, Front Genet)
In conclusion, this is the first extensive research on the correlation between PTPN family expression and immune characterization in BrCa. As results, PTPN7 expression is associated with immuno-hot tumors and could be a promising predictive biomarker for immunotherapy in not only BrCa but multiple cancers.
Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
2years
Spatial interplay between TIM3+, PD-L1+, PD-1+ and CLTA-4+ immune/ tumour cells using 18+1 BLEACH&STAIN mfIHC in more than 5 000 tissue samples. (ECP 2022)
BLEACH&STAIN facilitates deep profiling of 18 bio-markers in more than 40 different carcinoma entities and revealed complex changes in the spatial orchestration of a wide range of immune cell subsets that were driven by the expression profile and composition of TIM3, PD-L1, PD-1 and CTLA-4.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3) • ITGAX (Integrin Subunit Alpha X)
|
PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression • FOXP3 expression
almost3years
The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients: an impact on outcome. (PubMed, Ecancermedicalscience)
By multivariate Cox regression analysis, PD-L1+ TILs immunoreactivity score (p = 0.020) and CTLA-4+ TILs H. score (p = 0.036) were independent prognostic factors affecting overall survival among the other prognostic factors. PD-L1 and CTLA-4 expression by tumour cells could cooperate with each other in enhancing progression of CRC leading to poor patient outcome, while their expression by TILs could stand against tumour progression.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
almost3years
First-in-human phase 1 study of CD200 Activation Receptor-Ligand(CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma: Initial results from an ongoing clinical trial (SNO 2021)
METHODS Single-center, first-in-human, dose-escalation phase 1 clinical trial (NCT04642937) utilizing a 3 + 3 design initiated accrual in 12/2020 at dose level-1; CD200AR-L 3.75micrograms/kg/dose administered on days 1 and 2 by intradermal injection after topical imiquimod...RESULTS Between 12/2020 to 3/2021, 6 patients were enrolled on dose level-1; aged 37-65 years, 4 men, all with KPS >/= 80, and 3 patients on daily dexamethasone (4mg (n=2), 2mg (n=1))...IrICE symptoms were temporarily mitigated with ‘bevacizumab rescue protocol.’ No patients had local injection site reactions...CONCLUSION Initial dosing of CD200AR-L was well tolerated with early positive signal of immunological effect. Enrollment continues, now at dose level-2; CD200AR-L at 5micrograms/kg/dose.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD14 (CD14 Molecule) • CD200 (CD200 Molecule)
|
PD-L1 expression • CTLA4 expression • CD4 expression • PD-L1 expression + CTLA4 expression
|
Avastin (bevacizumab) • dexamethasone • Zyclara (imiquimod) • CD200AR-L
3years
A Hypoxia Signature for Predicting Prognosis and Tumor Immune Microenvironment in Adrenocortical Carcinoma. (PubMed, J Oncol)
Additionally, we found that PDL1 and CTLA4 expression were significantly lower in the high-risk group than in the low-risk group, and resting NK cells displayed a significant increase in the high-risk group. In summary, the hypoxia risk signature created in our study might predict prognosis and evaluate the tumor immune microenvironment for ACC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CCNA2 (Cyclin A2) • COL5A1 (Collagen Type V Alpha 1 Chain)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
over3years
PD-L1 x CTLA-4 in invasive bladder cancer (AUA 2021)
Our results demonstrate that, while some patients may benefit from PD-L1 based immunotherapy, for others, especially the non-respondents, CTLA-4 targeting may be promising. Therefore, as soon as CTLA-4 blockers are approved for bladder cancer, both markers should be tested.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD86 (CD86 Molecule)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
|
VENTANA PD-L1 (SP263) Assay
over3years
A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma. (PubMed, J Pathol)
Our results suggest OCCC from women of Asian and Caucasian descent share significant clinical and molecular similarities. To our knowledge, our study is the first study to include both Asian and Caucasian women with OCCC and helps shine light on the impact of ethnic differences on the immune microenvironment of OCCC.
Journal • Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • CTLA4 expression • PD-1 elevation • PD-L1 expression + CTLA4 expression
|
nCounter® PanCancer Immune Profiling Panel
over3years
[VIRTUAL] Tumors with homologous recombination repair deficiency signatures associate with an RNAseq profile profile suggestive of T cell-inflammation (AACR 2021)
Moreover, these data further suggest that homologous recombination repair deficiency may predispose tumors to a favourable milieu amenable to immunotherapies requiring T cell-inflammation. Understanding mediators of T cell-inflammation, both at cellular and genomic resolutions, may lead to improved predictors of response to current and novel immunotherapies and in turn improved patient outcomes for patients suffering from these diseases.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression